At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRKR Marker Therapeutics, Inc.
Pre-Mkt 11-04 06:57:30 EST
0.9829
+0.0818
+9.08%
High0.9991Low0.8928Vol94.61K
Open0.9051D1 Closing0.9011Amplitude11.80%
Mkt Cap16.39MTradable Cap13.88MTotal Shares16.67M
T/O90.24KT/O Rate0.67%Tradable Shares14.12M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Marker Therapeutics Receives $2.6 Million FDA Grant for Pancreatic Cancer Study
Reuters  ·  10-19
Marker Therapeutics Receives $2.6 Million FDA Grant for Pancreatic Cancer Study
Marker Therapeutics - Funding to Support Phase 1 Study of Mt-601 in Pancreatic Cancer
THOMSON REUTERS  ·  10-19
Marker Therapeutics - Funding to Support Phase 1 Study of Mt-601 in Pancreatic Cancer
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance Mt-601 in Pancreatic Cancer
THOMSON REUTERS  ·  10-19
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance Mt-601 in Pancreatic Cancer
Marker Therapeutics highlights expanded manufacturing support of CDMO partner
TIPRANKS  ·  09-22
Marker Therapeutics highlights expanded manufacturing support of CDMO partner
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  08-19
Calendar of U.S. Earnings Expected in the Week Ahead
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  08-17
Calendar of U.S. Earnings Expected in the Week Ahead
Marker Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-15
Marker Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Marker Therapeutics Q2 FY26 Net Loss Narrows 55% to USD 1.83 Million
Reuters  ·  08-15
Marker Therapeutics Q2 FY26 Net Loss Narrows 55% to USD 1.83 Million
Marker Therapeutics Inc Expected to Post a Loss of 22 Cents a Share - Earnings Preview
Reuters  ·  08-11
Marker Therapeutics Inc Expected to Post a Loss of 22 Cents a Share - Earnings Preview
Analysts Are Bullish on These Healthcare Stocks: Marker Therapeutics (MRKR), Tenax Therapeutics (TENX)
TIPRANKS  ·  07-10
Analysts Are Bullish on These Healthcare Stocks: Marker Therapeutics (MRKR), Tenax Therapeutics (TENX)
Marker Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-16
Marker Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Marker Therapeutics Q1 FY26 net loss narrows 28% to USD 3.18 million
Reuters  ·  05-16
Marker Therapeutics Q1 FY26 net loss narrows 28% to USD 3.18 million
Marker Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Reuters  ·  05-12
Marker Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Marker Therapeutics shareholders approved charter amendment boosting authorized common stock to 130 million shares
Reuters  ·  05-05
Marker Therapeutics shareholders approved charter amendment boosting authorized common stock to 130 million shares

Introduction

Company Name.
Marker Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Issue price:
--